Financial Performance - Total revenue reached $82.4 million, a 12% increase[7,40] - U S net product sales increased by 42% to $40.3 million[7,40] - Collaboration revenue was $42.1 million, a 7% decrease, but adjusting for a one-time settlement agreement milestone with DSE received in Q2 2024, it represents a 105% increase[40] - The company achieved its first quarter of operating income from ongoing business and anticipates sustainable profitability beginning in Q1 2026[4,40] - Cash and cash equivalents stand at $86.1 million[43] Marketing and Sales - Over 28,000 healthcare providers are now writing prescriptions for the company's products[9,20] - Retail prescription equivalents increased by 10% compared to Q1 2025[7,20,48] - The consumer statin intolerance website received over 650,000 visits in Q2, and the HCP statin intolerance site had over 600,000 click-throughs[15] - A balanced direct and digital marketing approach resulted in 23% of prescriptions written by physicians with only digital touchpoints and 38% of new writer prescriptions driven by digital-only touchpoints[17,20] Pipeline and Strategic Initiatives - The company is advancing IND-enabling studies for a new program in primary sclerosing cholangitis (PSC), representing an approximately $1 billion annual market opportunity, with potential first-in-human studies in 2H 2026[25,36] - Settlements were reached with three ANDA filers to protect NEXLETOL's IP until 2040[25]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 grew 63% year over year to $65 million after adjusting for a one-time milestone received in Q1 2024 [7][19] - U.S. net product revenue increased 41% year over year to $34.9 million, driven by expanded label and commercial initiatives [7][19] - Collaboration revenue decreased approximately 73% to $30.1 million due to the settlement agreement milestone with DSE, but grew 97% excluding that milestone [21] Business Line Data and Key Metrics Changes - U.S. product sales growth was impacted by a flat lipid market and seasonal headwinds, with script growth increasing only 2% sequentially compared to Q4 2024 [7][20] - The market access team achieved significant milestones, including the removal of prior authorizations for over 30 plans, enhancing access for patients [8][10] - The company expanded its field reimbursement support team threefold to 15 specialists, improving support for prescribers [7][38] Market Data and Key Metrics Changes - The company reported that approximately 472,500 patients have been treated with its therapies in Europe, with royalty revenue from DSE increasing 8% from Q4 2024 to $10.5 million in Q1 2025 [13][14] - The Japanese market is expected to be a significant contributor, with approval for bempedoic acid anticipated in the second half of 2025 [14] Company Strategy and Development Direction - The company is focused on revenue growth, portfolio expansion, and pipeline advancement, with a commitment to improving cardiovascular health [5][23] - A new triple combination product is being developed, expected to provide significant LDL cholesterol reduction and is projected for commercialization in 2027 [12][62] - The company aims to leverage its leadership in ACLY biology and expand into high-need indications, such as primary sclerosing cholangitis (PSC) [16] Management's Comments on Operating Environment and Future Outlook - Management noted that the first quarter faced challenges due to changes in Medicare Part D and higher out-of-pocket costs, but early Q2 trends show prescription volume tracking approximately 8% higher than Q1 [20][58] - The management expressed confidence in the strategic initiatives to drive growth and improve patient access to innovative therapies [23][24] Other Important Information - The company reiterated its full-year 2025 operating expense guidance of approximately $215 million to $235 million, including $15 million in non-cash expenses related to stock compensation [22] - The company is actively pursuing new business development opportunities and is not waiting for specific milestones to execute deals [29] Q&A Session Summary Question: When should we expect a new business development deal? - Management is making good progress but will not set a timeline for a deal, as they want to ensure it makes sense for the company [29] Question: Is the triple combination a defensive strategy? - The triple combination is seen as a convenient option for patients, potentially being the most efficacious LDL-lowering drug on the market [31] Question: Is the sales force right-sized? - The current sales force of approximately 155 representatives is deemed appropriate, balancing personal and digital promotion [37] Question: How is the company addressing physician education on statin intolerance? - The company is focusing on educating physicians about statin intolerance, with significant traction in messaging about the unmet need for patients who cannot tolerate statins [40] Question: What is the gross margin trajectory? - Gross margin is influenced by the sales mix between U.S. and partner sales, with expectations for improvement as tech transfer progresses [65]